6:30 PM - 6:35 PM Welcome and Introduction
R Advani, MD, Program Director and Moderator
6:35 PM - 7:00 PM Overview Hodgkin Lymphoma
- Disease subtypes
- Risk stratification
7:00 PM – 8:50 PM Case Discussions
- Initial Therapy Considering Disease Stage and Presentation
- Response-Adapted Therapy
- Preventing/Delaying Post-ASCT Relapse
- Therapy at Disease Progression Considering Treatment History
For each case presented the faculty will discuss available clinical data and its use in guiding treatment decisions.
Faculty Panel Discussion and Audience Questions
Clinical Trial Spotlight of Preview of Key ASH 2017 Presentations and Ongoing Studies
8:50 PM – 9:20 PM Novel and Investigational Treatments for Hodgkin Lymphoma
9:20 PM – 9:30 PM Final Thoughts and Audience Q&A
Date / Time
Ranjana Advani, MD
Professor of Medicine
Department of Oncology
Stanford University Medical Center
Stanford Cancer Center
Robert W. Chen, MD
Department of Hematology
City of Hope
Andrew Evens, DO, MSc, FACP
Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Pier Luigi Zinzani, MD, PhD
Professor of Hematology
Chief of Lymphoma and CLL Unit
Institute of Hematology "Seràgnoli"
University of Bologna
The primary purpose of this program is to provide clinicians with expert recommendations and insights to address current clinical management issues and challenges for patients with Hodgkin lymphoma. To accomplish this, the program will emphasize interactive case presentations with expert panel discussions and debate of available therapeutic strategies.
The goal of this activity is to improve participants’ competence in and performance at selecting treatment for individual patients with Hodgkin lymphoma.
This program is intended for physicians and other healthcare providers who care for patients with Hodgkin lymphoma.
- Assess the results of recent trials of response-adapted frontline therapy in Hodgkin lymphoma and how they will influence clinical practice
- Choose optimal intensified frontline treatments for patients with advanced Hodgkin lymphoma incorporating available and emerging treatment options
- Describe the application and limitations of FDG-PET imaging in the early assessment of response to treatment in Hodgkin lymphoma
- Plan therapeutic strategies to prevent second relapse after transplantation in patients with Hodgkin lymphoma at risk of progression
- Evaluate the clinical data on available and promising investigational agents for patients with relapsed/refractory Hodgkin lymphoma
- Determine optimal sequencing of brentuximab vedotin and immune checkpoint inhibitors in the treatment of patients with Hodgkin lymphoma
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.